Clinical trial readout dates for Rhythm Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.
The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.
| Phase 3 Setmelanotide Obesity Associated With Defects in Leptin-melanocortin Pathway · NCT06596135 | June 2026 Primary data collected |
| Phase 3 Setmelanotide Hypothalamic Obesity; Multiple Pituitary Hormone Deficiency Genetic Form · NCT06760546 | March 2027 Recruiting |
| Phase 1/2 Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) Hypothalamic Obesity; Prader-Willi Syndrome · NCT06239116 | May 2027 Ongoing |
| Phase 2 Bivamelagon Hypothalamic Obesity · NCT07156578 | April 2028 Enrolling |
These dates have elapsed; the company may have reported, or guidance may have shifted.
| Phase 2 Setmelanotide Prader-Willi Syndrome; Obesity · NCT06772597 | November 2026 Ongoing |
Rhythm Pharmaceuticals Inc. reported $321M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $41M; at that rate the cash would last about 8 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-03 |